SELLAS Life Sciences Group, Inc. (SLS) announced the preliminary data from Phase 2a trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia and successful filing of a provisional patent application around the ASXL1 mutation and SLS009, including all CDK9 inhibitor drugs.

塞拉斯生命科学集团（SLS）宣布了SLS009（一种高选择性CDK9抑制剂）在复发/难治性急性髓细胞白血病中的2a期试验的初步数据，并成功提交了ASXL1突变和SLS009（包括所有CDK9抑制剂药物）的临时专利申请。

The company said, as of April 19, data cutoff, a 57% overall response rate has been achieved thus far, in the selected optimal dose regimen of 30 mg BIW, far surpassing the targeted 20% rate.SELLAS plans to initiate discussions with the FDA about the potential for an accelerated approval pathway with SLS009 in the ASXL1 molecularly defined r/r AML population as well as in patients harboring this mutation in other indications..

该公司表示，截至4月19日数据截止，迄今为止，在选定的30毫克白车身的最佳剂量方案中，总体缓解率达到了57%，远远超过了目标的20%。SELLAS计划与FDA开始讨论在ASXL1分子定义的r/r AML人群以及在其他适应症中携带这种突变的患者中，SLS009加速批准途径的可能性。。

For More Such Health News, visit rttnews.com. For comments and feedback contact: editorial@rttnews.comBusiness News

有关更多此类健康新闻，请访问rttnews.com。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局决定生物技术股